# Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer

> **NCT06391190** · PHASE1,PHASE2 · RECRUITING · sponsor: **RenJi Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Locally Advanced Cervical Carcinoma
- Concurrent Chemoradiotherapy
- Immunotherapy

## Interventions

- **DRUG:** Albumin-Bound Paclitaxel, cisplatin, Sintilimab

## Key facts

- **NCT ID:** NCT06391190
- **Lead sponsor:** RenJi Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-01-01
- **Primary completion:** 2024-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06391190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06391190, "Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06391190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*